VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
Schafroth C, Galván JA, Centeno I, Koelzer VH, Dawson HE, Sokol L, Rieger G, Berger MD, Hädrich M, Rosenberg R, Nitsche U, Schnüriger B, Langer R, Inderbitzin D, Lugli A, Zlobec I.
Schafroth C, et al. Among authors: lugli a.
Oncotarget. 2015 Dec 8;6(39):41453-63. doi: 10.18632/oncotarget.6162.
Oncotarget. 2015.
PMID: 26496026
Free PMC article.